Browsing by author "AHern, Roger"
Now showing items 1-6 of 6
-
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; et al. (2012-05)Background The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ... -
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
Natrajan, R; Wilkerson, PM; Marchiò, C; Piscuoglio, S; Ng, CKY; et al. (2014-04)Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen ... -
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Dowsett, M; Smith, IE; Ebbs, SR; Dixon, JM; Skene, A; et al. (2006-02)The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine treatment of breast cancer has become increasingly popular, particularly using the nuclear marker Ki67, and holds the ... -
Short-term presurgical treatment for all?
Dowsett, M; Salter, J; Hills, M; Detre, S; A'Hern, R; et al. (BIOMED CENTRAL LTD, 2007-01-01) -
Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy.
Martin, S; Sydenham, M; Haviland, J; A'Hern, R; Owen, R; et al. (2010-10)Purpose To test for association between single nucleotide polymorphisms at the TGFβ1 locus and the risk of late normal tissue injury following whole breast radiotherapy.Methods A retrospective study compared the number of ... -
Who would have thought a single Ki67 measurement would predict long-term outcome?
Dowsett, M; A'Hern, R; Salter, J; Zabaglo, L; Smith, IE (2009-01)